Advancing Cancer Diagnostics with Qritive’s AI Modules

Watch the video to learn how our AI modules are transforming modern pathology workflows.

Singapore, January 17, 2024 — Qritive offers a growing portfolio of AI-powered diagnostic modules designed to support pathologists in identifying, grading, and classifying disease areas on whole-slide images (WSIs). These modules deliver fast, accurate, and reproducible results, helping reduce interpretation variability, improve consistency, and accelerate turnaround times.

From prostate and colon cancer detection to lymph node metastasis assessment, our AI solutions address key diagnostic challenges across various tissue types. Each module is hardware agnostic and easily integrates into existing digital pathology workflows, including LIS and image management platforms—alongside full compatibility with Qritive’s Pantheon™ platform.

About Qritive

Qritive, headquartered in Singapore with operations in the US and India, is transforming digital pathology through advanced AI-powered solutions that support cancer diagnosis and improve health outcomes.

By leveraging cutting-edge deep learning technology, Qritive supports pathologists in the interpretation of pathology assessments and enhances pathology workflows—enabling faster, more accurate diagnoses and reducing time to treatment.

Qritive is committed to empowering healthcare professionals around the world with tools that promote collaboration and high performance, regardless of complexity or distance.

Get in Touch

Want to learn more about our solutions or explore potential collaborations?

Visit www.qritive.com or contact us at info@qritive.com